Literature DB >> 21897452

A 7-year-old with pulmonary hypertension.

James Olin1, Steven Abman, R Grady, D Ivy, Mark Lovell, David Partrick, Vivek Balasubramaniam.   

Abstract

The authors discuss the case of a 7-year-old female who presented with exertional cyanosis and was found to have pulmonary arterial hypertension. Despite normal left-sided heart function, the patient developed pulmonary oedema in response to pulmonary vasodilator therapy, increasing suspicion for pathology in the pulmonary capillaries and veins. Lung biopsy confirmed a diagnosis of pulmonary capillary haemangiomatosis (PCH), a rare cause of pulmonary hypertension in both children and adults. The diagnosis requires lung biopsy and is often made postmortem. She was treated with interferon α-2a and doxycycline for their antiangiogenic properties and reports of disease regression. Although she initially demonstrated improvement in her pulmonary hypertension in response to these medications, she succumbed to the disease within the time frame previously reported for PCH.

Entities:  

Year:  2011        PMID: 21897452      PMCID: PMC3082056          DOI: 10.1136/bcr.02.2011.3843

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  25 in total

1.  Pulmonary capillary hemangiomatosis-like foci. An autopsy study of 8 cases.

Authors:  D M Havlik; L W Massie; W L Williams; L A Crooks
Journal:  Am J Clin Pathol       Date:  2000-05       Impact factor: 2.493

Review 2.  Updated clinical classification of pulmonary hypertension.

Authors:  Gérald Simonneau; Ivan M Robbins; Maurice Beghetti; Richard N Channick; Marion Delcroix; Christopher P Denton; C Gregory Elliott; Sean P Gaine; Mark T Gladwin; Zhi-Cheng Jing; Michael J Krowka; David Langleben; Norifumi Nakanishi; Rogério Souza
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

3.  Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a.

Authors:  C W White; H M Sondheimer; E C Crouch; H Wilson; L L Fan
Journal:  N Engl J Med       Date:  1989-05-04       Impact factor: 91.245

4.  Interferon alpha 2a down-regulates VEGF expression through PI3 kinase and MAP kinase signaling pathways.

Authors:  Wei-Zhong Wu; Hui-Chuan Sun; Yue-Fang Shen; Jie Chen; Lu Wang; Zhao-You Tang; George Iliakis; Kang-Da Liu
Journal:  J Cancer Res Clin Oncol       Date:  2004-12-11       Impact factor: 4.553

5.  Pulmonary capillary hemangiomatosis: a unique feature of congestive vasculopathy associated with hypertrophic cardiomyopathy.

Authors:  X Jing; T Yokoi; Y Nakamura; M Nakamura; L Shan; S Tomimoto; T Hano; K Kakudo
Journal:  Arch Pathol Lab Med       Date:  1998-01       Impact factor: 5.534

6.  Pulmonary edema complicating prostacyclin therapy in pulmonary hypertension associated with scleroderma: a case of pulmonary capillary hemangiomatosis.

Authors:  M K Gugnani; C Pierson; R Vanderheide; R E Girgis
Journal:  Arthritis Rheum       Date:  2000-03

7.  Interferon-alpha-induced inhibition of B16 melanoma cell proliferation: interference with the bFGF autocrine growth circuit.

Authors:  M Torcia; M Lucibello; G De Chiara; D Labardi; L Nencioni; P Bonini; E Garaci; F Cozzolino
Journal:  Biochem Biophys Res Commun       Date:  1999-09-07       Impact factor: 3.575

8.  Pulmonary capillary hemangiomatosis incidentally detected in a lobectomy specimen for a metastatic colon cancer.

Authors:  Suzuko Moritani; Shu Ichihara; Yukio Seki; Masato Kataoka; Toyoharu Yokoi
Journal:  Pathol Int       Date:  2006-06       Impact factor: 2.534

9.  Pulmonary capillary hemangiomatosis arising in hereditary hemorrhagic telangiectasia.

Authors:  Heike Varnholt; Richard Kradin
Journal:  Hum Pathol       Date:  2004-02       Impact factor: 3.466

10.  Familial pulmonary capillary hemangiomatosis resulting in primary pulmonary hypertension.

Authors:  D Langleben; J M Heneghan; A P Batten; N S Wang; N Fitch; R D Schlesinger; A Guerraty; J L Rouleau
Journal:  Ann Intern Med       Date:  1988-07-15       Impact factor: 25.391

View more
  1 in total

1.  Recombinant human interferon alpha 2b prevents and reverses experimental pulmonary hypertension.

Authors:  Eileen M Bauer; Han Zheng; Michael T Lotze; Philip M Bauer
Journal:  PLoS One       Date:  2014-05-16       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.